| Bioactivity | Emapalumab (NI-0501) is a humanized monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH)[1]. |
| Invitro | Emapalumab (NI-0501) impairs IFNcR1 and IFNc-Receptor-2 (IFNcR2) interaction induced by IFNc at the cell surface. |
| Name | Emapalumab |
| CAS | 1709815-23-5 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vallurupalli M, et, al. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019 Nov 21;134(21):1783-1786. |